Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 5:13 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | ARCH Venture Fund XII L.P. | 3,728,738 10.200% | 3,728,738 (New Position) | View |
| 2024-11-14 3:11 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | Cormorant Asset Management LP | 2,940,921 8.040% | 638 (+0.02%) | View |
| 2024-11-13 12:26 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | Capital International Investors | 2,602,529 7.100% | 2,602,529 (New Position) | View |
| 2024-11-12 10:34 am Purchase | 13G | Rapport Therapeutics Inc. RAPP | FMR LLC | 5,486,468 14.999% | 503,117 (+10.10%) | View |
| 2024-10-18 5:23 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | JOHNSON & JOHNSON JNJ | 2,498,051 6.800% | 2,498,051 (New Position) | View |
| 2024-07-10 10:10 am Purchase | 13G | Rapport Therapeutics Inc. RAPP | FMR LLC | 4,983,351 13.624% | 4,983,351 (New Position) | View |
| 2024-06-24 9:00 pm Sale | 13G | Rapport Therapeutics Inc. RAPP | GOLDMAN SACHS GROUP INC GS | 1,285,188 3.500% | -1,380,494 (-51.79%) | View |
| 2024-06-21 4:52 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | GOLDMAN SACHS GROUP INC GS | 2,665,682 7.500% | 2,665,682 (New Position) | View |
| 2024-06-20 4:01 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | Cormorant Asset Management LP | 2,940,283 8.040% | 2,940,283 (New Position) | View |
| 2024-06-14 3:59 pm Purchase | 13D | Rapport Therapeutics Inc. RAPP | Sofinnova Venture Partners XI L.P. | 1,951,562 5.500% | 1,951,562 (New Position) | View |